Mitral Valve Prolapse

Mitral valve prolapse (MVP) is a common heart condition characterized by the abnormal displacement (prolapse) of one or both mitral valve leaflets into the left atrium during ventricular systole. This displacement is often due to myxomatous degeneration, causing the leaflets to become thickened and redundant. While frequently benign and asymptomatic, MVP can lead to mitral regurgitation, arrhythmias, and, in rare cases, more severe complications.

The etiology of MVP is often idiopathic, but a significant genetic component is recognized. It can be primary (isolated) or secondary to various conditions.

• Genetic Factors: Familial MVP is common, often inherited in an autosomal dominant pattern. It is strongly associated with connective tissue disorders such as Marfan syndrome, Ehlers-Danlos syndrome, osteogenesis imperfecta, and pseudoxanthoma elasticum.


• Congenital Anomalies: Can be associated with congenital heart defects.


• Inflammatory/Infectious: History of rheumatic fever (less common as a direct cause, but can contribute to valvular changes), infective endocarditis.


• Ischemic Heart Disease: Papillary muscle dysfunction due to ischemia can lead to secondary MVP.


• Other Conditions: Hypertrophic cardiomyopathy, polycystic kidney disease, Wolff-Parkinson-White syndrome, scoliosis, pectus excavatum.

The fundamental pathology in primary MVP is myxomatous degeneration, involving the deposition of proteoglycans and an increase in collagen disorganization within the spongiosa layer of the mitral valve leaflets and chordae tendineae. This leads to:

1. Leaflet Redundancy and Elongation: The leaflets become thicker, more pliable, and elongated.


2. Chordae Elongation/Rupture: The chordae tendineae may become elongated, contributing to the leaflet prolapse, or in severe cases, rupture.


3. Annular Dilation: The mitral annulus may dilate, exacerbating the prolapse and potential regurgitation.

MVP is one of the most common valvular heart conditions, affecting approximately 2-3% of the general population. It is more prevalent in women than men, with a ratio of about 2:1, although severe forms and complications tend to be more common in men and older individuals. The incidence tends to increase with age.

• Female gender
• Family history of MVP
• Connective tissue disorders (Marfan syndrome, Ehlers-Danlos syndrome)
• Scoliosis and other chest wall deformities (e.g., pectus excavatum)
• Hyperthyroidism
• Long QT syndrome
• Wolff-Parkinson-White syndrome

A. Early Symptoms

• Often asymptomatic and discovered incidentally. B. Common Symptoms


• Palpitations (due to premature beats or arrhythmias)


• Atypical chest pain (non-exertional, sharp, or dull, often prolonged)


• Fatigue


• Dyspnea (shortness of breath), especially on exertion


• Lightheadedness or dizziness C. Advanced Symptoms


• Symptoms of heart failure (if severe mitral regurgitation develops): progressively worsening dyspnea, orthopnea, paroxysmal nocturnal dyspnea, edema.


• Syncope (fainting)


• Stroke or transient ischemic attack (TIA) symptoms (rare, due to emboli) D. Emergency Symptoms


• Acute onset severe dyspnea


• Severe chest pain not relieved by rest


• Sudden weakness or neurological deficits (indicating stroke)


• Fever, chills, and new murmur (suggesting infective endocarditis)

• Vital Signs: Usually normal; may have tachycardia during palpitations.
• Inspection: May reveal skeletal abnormalities such as scoliosis or pectus excavatum.
• Palpation: Precordial impulse may be normal or hyperdynamic if regurgitation is severe.

• Late systolic murmur: A crescendo-decrescendo murmur that follows the click, indicative of mitral regurgitation. The duration and intensity correlate with the severity of regurgitation.
• Dynamic auscultation: Standing or Valsalva maneuver decreases ventricular volume, making the click occur earlier and the murmur longer/louder. Squatting or handgrip increases ventricular volume, delaying the click and shortening/softening the murmur.

A. Clinical Assessment
Detailed history of symptoms, family history, and thorough physical examination focusing on cardiac auscultation.
B. Laboratory Testing
Generally not diagnostic for MVP itself but may be used to evaluate complications or associated conditions.
C. Imaging Studies
Echocardiography is the gold standard.
D. Functional Tests
Exercise stress testing may be used to assess symptoms like dyspnea or exercise-induced arrhythmias.
E. Biopsy Findings
Not routinely performed for MVP; relevant only for systemic connective tissue diseases if suspected.
F. Genetic Testing
Considered for patients with a strong family history or features suggestive of underlying connective tissue disorders (e.g., Marfan syndrome).
G. Differential Diagnosis
Must distinguish from other causes of chest pain, palpitations, or murmurs.

Complete Blood Count (CBC)
Type: Blood Test
Purpose: Assess for anemia or signs of infection (e.g., in endocarditis).
Expected Findings: Usually normal in uncomplicated MVP.
Interpretation: Abnormalities suggest secondary conditions or complications. Electrolytes and Renal Function Tests
Type: Blood Test
Purpose: Evaluate overall health and potential impact of heart failure if severe regurgitation is present.
Expected Findings: Usually normal.
Interpretation: May show abnormalities if renal function is compromised due to severe heart failure. Cardiac Troponins
Type: Blood Test
Purpose: Rule out myocardial ischemia in patients presenting with chest pain.
Expected Findings: Normal in MVP-related chest pain.
Interpretation: Elevated levels indicate myocardial injury. Genetic Testing for Connective Tissue Disorders (e.g., FBN1 for Marfan)
Type: Blood Test (DNA analysis)
Purpose: Identify genetic mutations associated with inherited connective tissue disorders when MVP is part of a syndromic presentation.
Expected Findings: Specific mutations depending on the suspected disorder.
Interpretation: Presence of pathogenic mutation supports the diagnosis of a specific connective tissue disorder.

Echocardiography (Transthoracic Echocardiogram - TTE)
Purpose: Gold standard for diagnosing MVP, assessing leaflet morphology, degree of prolapse, and severity of mitral regurgitation.
Typical Findings: M-mode and 2D echocardiography show systolic displacement of one or both mitral leaflets >2 mm beyond the mitral annular plane. Doppler studies quantify mitral regurgitation. Myxomatous thickening (>5mm) of leaflets is often seen.
Clinical Importance: Confirms diagnosis, guides management, risk stratification, and monitors progression. Transesophageal Echocardiography (TEE)
Purpose: Provides more detailed views of the mitral valve leaflets and subvalvular apparatus, especially useful when TTE is inconclusive or surgical planning is needed.
Typical Findings: High-resolution images of prolapse, leaflet thickening, chordal rupture, and precise assessment of regurgitation jet.
Clinical Importance: Essential for surgical planning, evaluation of infective endocarditis, and when TTE is limited. Cardiac Magnetic Resonance Imaging (CMR)
Purpose: Provides comprehensive assessment of cardiac structure and function, including precise quantification of ventricular volumes and mitral regurgitation, and myocardial fibrosis.
Typical Findings: Excellent visualization of valve anatomy, quantification of regurgitation fraction, and detection of myocardial scarring (late gadolinium enhancement).
Clinical Importance: Useful for equivocal echocardiograms, assessing right ventricular function, and identifying myocardial fibrosis which may correlate with arrhythmias. Chest X-ray
Purpose: Assess for cardiomegaly, pulmonary congestion (if severe regurgitation/heart failure), and skeletal abnormalities.
Typical Findings: Often normal in uncomplicated MVP. May show cardiomegaly or pulmonary vascular congestion in advanced cases.
Clinical Importance: Baseline assessment, helpful in evaluating complications like heart failure.

• Coronary Artery Disease: Distinguish MVP-related chest pain from angina (MVP pain is often atypical, non-exertional, prolonged).
• Anxiety Disorders/Panic Attacks: Can mimic palpitations and chest pain.
• Other Valvular Heart Diseases: Aortic stenosis, hypertrophic cardiomyopathy (different murmur characteristics and associated findings).
• Pericarditis/Myocarditis: Can cause chest pain and dyspnea.
• Arrhythmias from other causes: Paroxysmal supraventricular tachycardia, atrial fibrillation.
• Skeletal/Musculoskeletal Chest Pain: Costochondritis, rib fractures.

• Mitral Regurgitation (MR): The most common complication, ranging from mild to severe, potentially leading to left ventricular dilation and heart failure.
• Arrhythmias: Supraventricular (e.g., atrial fibrillation) and ventricular arrhythmias (e.g., premature ventricular contractions, ventricular tachycardia), which can cause palpitations, dizziness, or syncope.
• Infective Endocarditis: Increased risk, particularly if MR is present or with previous valve damage.
• Thromboembolic Events (Stroke/TIA): Rare, but can occur due to platelet aggregation on the prolapsing valve or in the setting of atrial fibrillation.
• Sudden Cardiac Death (SCD): Extremely rare, but MVP is a recognized cause, particularly in patients with severe MR, significant arrhythmias, or connective tissue disorders.
• Chordal Rupture: Can acutely worsen mitral regurgitation and lead to heart failure.

A. Lifestyle Modifications

• Avoid stimulants: Limit caffeine, nicotine, and other stimulants that can trigger palpitations.


• Regular exercise: Generally encouraged, but strenuous exercise may be limited in those with severe regurgitation or arrhythmias.


• Hydration: Maintain adequate fluid intake.


• Stress reduction: Techniques for managing anxiety. B. Preventive Measures


• Antibiotic prophylaxis for infective endocarditis: No longer routinely recommended for isolated MVP unless there is a history of endocarditis or presence of specific high-risk features (e.g., prior valve surgery, prosthetic valve, unrepaired congenital heart disease).


• Regular follow-up: Clinical and echocardiographic monitoring for progression, especially in those with moderate to severe regurgitation. C. Medical Treatment

• Examples: Metoprolol, Bisoprolol.

• Examples: Flecainide, Sotalol (chosen based on arrhythmia type and severity).

• Indication: Only recommended for MVP patients with a history of stroke/TIA, atrial fibrillation, or other high-risk factors for thrombus formation. D. Surgical Treatment


• Mitral valve repair: The preferred surgical approach for severe mitral regurgitation due to MVP, especially when repair is feasible. Involves techniques like leaflet resection, annuloplasty, and chordal replacement.


• Mitral valve replacement: Performed if valve repair is not feasible, involving prosthetic mechanical or bioprosthetic valves. E. Interventional Procedures

• Indication: Severe primary or secondary mitral regurgitation in selected patients. F. Rehabilitation


• Cardiac rehabilitation programs may be beneficial for patients recovering from valve surgery, focusing on exercise, education, and lifestyle modification. G. Emergency Management


• Acute severe mitral regurgitation: Management may include vasodilators (e.g., nitroglycerin, nitroprusside), diuretics, and inotropic agents. Intra-aortic balloon pump may be considered. Urgent surgical intervention may be required.


• Acute neurological events (stroke/TIA): Standard stroke protocols, including thrombolysis or thrombectomy as indicated.

The prognosis for most individuals with MVP is excellent, especially for those who are asymptomatic and without significant mitral regurgitation. They generally have a normal life expectancy. The prognosis worsens with the development of significant mitral regurgitation, atrial fibrillation, or other complications. Patients with severe symptomatic mitral regurgitation who undergo successful valve repair or replacement also have a good prognosis.

• Primary Prevention: There is no known primary prevention for the development of MVP itself, as it's often idiopathic or genetically predisposed.
• Secondary Prevention: Focuses on preventing complications in individuals diagnosed with MVP. This includes regular medical follow-up, management of symptoms, and monitoring for the progression of mitral regurgitation or development of arrhythmias. Education on symptoms of endocarditis and the importance of good dental hygiene.

The following homeopathic remedies have been historically indicated for symptoms associated with Mitral Valve Prolapse. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Mitral Valve Prolapse.